However, despite many published results, the association of CHEK2 mutations with ovarian cancer (or its particular non-high-grade subtypes) can be neither confirmed nor rejected, and it illustrates the stalemate situation with the clinical interpretation of germline CHEK2 variants [115,260,261,262,263]. The gene discussed is CHEK2; the disease is ovarian carcinoma.